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Candida lusitaniae is usually susceptible to echinocandins. Beta-1,3-glucan synthase encoded by FKS genes is the target of echi-
nocandins. A fewmissense mutations in the C. lusitaniae FKS1 hot spot 1 (HS1) have been reported. We report here the rapid
emergence of antifungal resistance in C. lusitaniae isolated during therapy with amphotericin B (AMB), caspofungin (CAS), and
azoles for treatment of persistent candidemia in an immunocompromised child with severe enterocolitis and visceral adenoviral
disease. As documented from restriction fragment length polymorphism (RFLP) and random amplified polymorphic DNA
(RAPD) analysis, the five C. lusitaniae isolates examined were related to each other. From antifungal susceptibility and molecu-
lar analyses, 5 different profiles (P) were obtained. These profiles included the following: profile 1 (P1) (CASMIC [g/ml], 0.5;
fluconazole [FLC]MIC, 0.25), determined while the patient was being treated with liposomal AMB for 3 months; P2 (FLCMIC
[g/ml], 0.25; CASMIC, 4), while the patient was being treated with CAS for 2 weeks; P3 (CASMIC [g/ml], 0.5; FLCMIC, 32),
while the patient was being treated with azoles and CAS initially followed by azoles alone for a week; P4 (CASMIC [g/ml], 8;
FLCMIC, 8), while the patient was being treated with both drugs for 3 weeks; and P5 (AMBMIC [g/ml], 0.125; CASMIC, 8),
while the patient was being treated with AMB and FLC for 2 weeks. CAS resistance was associated with resistance not only to
micafungin and anidulafungin but also to AMB. Analysis of CAS resistance revealed 3 novel FKS1mutations in CAS-resistant
isolates (S638Y in P2; S631Y in P4; S638P in P5). While S638Y and -P are within HS1, S631Y is in close proximity to this domain
but was confirmed to confer candin resistance using a site-directed mutagenesis approach. FLC resistance could be linked with
overexpression of major facilitator gene 7 (MFS7) in C. lusitaniae P2 and P4 and was associated with resistance to 5-flurocyto-
sine. This clinical report describes resistance of C. lusitaniae to all common antifungals. While candins or azole resistance fol-
lowedmonotherapy, multidrug antifungal resistance emerged during combined therapy.
Candida lusitaniae, an opportunistic haploid yeast, remains arare cause of candidemia.WhileC. lusitaniae can develop am-
photericin B (AMB) resistance (1, 2), it is considered generally
susceptible to all systemic antifungal agents (3). Echinocandins
are used as first-line therapy for candidemia due to C. lusitaniae.
The target of echinocandins is -1,3-glucan synthase and is en-
coded by FKS genes (4). Three echinocandins, anidulafungin
(ANI), caspofungin (CAS), and micafungin (MICA), have been
available andwidely used for about a decade. As a result, emerging
resistance to echinocandins has been reported in several species,
including C. albicans, C. dubliniensis, C. kefyr, C. glabrata, C. kru-
sei, C. tropicalis, and C. lusitaniae (5–12). Missense mutations in
FKS genes (FKS1 and FKS2) that are situated in different regions
(host spot 1 [HS1] and HS2) are responsible for the increase of
drug MICs compared to the MICs seen with wild-type isolates.
These MIC increases were shown to cause treatment failures in
animal experiments similarly to those seen in clinical cases, thus
suggesting the emergence of clinical resistance (13). In C. lusita-
niae, a single missense mutation in C. lusitaniae FKS1HS1 at po-
sition 645 (S645F) was reported in clinical isolates and resulted in
increased MICs of several echinocandins. While recent data doc-
umented cross-resistance between echinocandins and azoles in C.
glabrata (14), no cross-resistance has yet been reported in C. lus-
itaniae. The present paper reports the unusual emergence of clin-
ical isolates of C. lusitaniae with documented cross-resistance to
candins and azoles following exposure to various antifungal regi-
mens for persistent candidemia.
MATERIALS AND METHODS
Strains and media. C. lusitaniae strains were grown in complete yeast
extract-peptone-dextrose (YEPD) medium (1% Bacto peptone [Difco
Laboratories, Basel, Switzerland], 0.5% yeast extract [Difco]) with 2%
(wt/vol) glucose (Fluka, Buchs, Switzerland). Saccharomyces cerevisiaewas
grown on YEPD medium for isolate precultures and on yeast nitrogen
base (YNB) agar (Difco) with 2% (wt/vol) glucose. Species identification
was performed using matrix-assisted laser desorption ionization–time of
flight (MALDI-TOF) mass spectrometry (MS) Microflex LT systems
(Bruker Daltonics GmbH, Leipzig, Germany) and with analysis of data
using FlexControl (version 3.0) software (Bruker Daltonics) as described
in reference 15.
Susceptibility assays. Determinations of drug MICs for C. lusitaniae
clinical isolates according to EUCAST guidelines were performed in
RPMI 1640 medium (Sigma-Aldrich, Switzerland) with 2% glucose and
in flat-well microtiter plates. RPMI 1640 buffered at pH 7.0 with MOPS
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(morpholinepropanesulfonic acid) was used for MIC tests of azoles,
5-fluorocytosine (5-FC), candins, and AMB. Cells were diluted to a den-
sity of 0.5 2  105 to 2  105 cells/ml. All compounds were dissolved to
obtain final concentrations ranging from 128 g/ml to 0.0162 g/ml.
Plates were incubated at 35°C for 24 h, and readings were carried out in a
microplate reader at 540 nm. The MIC was defined as the drug concen-
tration at which the optical density was 50% of that of the drug-free
culture. Quality controls included C. albicans strain ATCC 928. Antifun-
gal agents used in this study were provided as pure substances by pharma-
ceutical companies (CAS, Merck; micafungin [MICA], Astellas; anidula-
fungin [ANI] and FLC, Pfizer). AMB deoxycholate (Fungizone) was
obtained from Bristol-Myers Squibb (Cham, Switzerland).
RLFP and RAPD analysis. The recovered C. lusitaniae isolates were
subjected to restriction fragment length polymorphism (RLFP) and ran-
dom amplified polymorphic DNA (RAPD) analysis as described else-
where (16). Genomic DNA was isolated by glass bead extraction from
each isolate as previously described (17) and was subjected to EcoRI and
MspI digestion. RAPD analysis was performed with primer OPE-18 (GG
ACTGCAGA) as previously recommended (16). Gel electrophoresis was
carried out with 0.8% agarose followed by ethidium bromide staining.
Additional software (ImageJ) (18) was used to corroborate our findings
from the RFLP analysis (see Fig. S1 in the supplemental material).
FKS1 sequencing.Primers were used to amplify FKS1 alleles encoding
-glucan synthase from C. lusitaniae isolates (19). These primers were
designed to amplify conserved HS1 (hot spot region 1) and HS2 regions
(for HS1, MDO002 [GCCTTTGGGTGGTTTGTTTA] and MDO003 [T
CGGAATCTCTTGGGAAGAA]; for HS2, MDO004 [TGCTGGTATGG
GTGAACAGA] and MDO005 [CGAACACTTCGAAGAATGGAG]). Se-
quencing procedures were performed with the same primers and are
described elsewhere (20). Sequence alignments were performed with Ge-
neious software (Biomatters Ltd., New Zealand).
qRT-PCR. Quantitative reverse transcription-PCR (qRT-PCR) was
performed as described elsewhere (21). Total RNA was extracted from
log-phase cultures with an RNeasy Protect minikit (Qiagen) by a process
involving mechanical disruption of the cells with glass beads and an
RNase-free DNase treatment step as previously described (22). Gene ex-
pression levels were determined by real-time qRT-PCR in a StepOne real-
time PCR system (Applied Biosystems) using a Mesa Blue quantitative
PCR (qPCR) Mastermix Plus for Sybr assay kit (Eurogentec). Each reac-
tion was run in triplicate on three separate occasions. Expression levels
were normalized toACT1 expression. Primers forC. lusitaniaeATP-bind-
ing cassette (ABC) and major facilitator superfamily (MFS) transporter
genes were designed with Primer3Plus. The primers were chosen on the
basis of the available genome sequences (Broad Institute). Primers are
listed in Table S1 in the supplemental material. Gene names were given
according to the work of Reboutier et al. (23). Primers ABC15-F and
ABC15-R as well as primers ABC9-F and ABC9-R were selected from the
C. lusitaniae genomes of the closest homologs of the C. albicans CDR1
gene. MFS7-R and MFS7-F as well as ABC12-R and ABC12-F were se-
lected since the corresponding genes were previously shown to be differ-
entially expressed in several C. lusitaniae isolates (23).
Construction of FKS1mutants. In order to introduce specific muta-
tions in FKS1 for testing their effect on echinocandin susceptibility, the
model yeast S. cerevisiae was used in combination with the clustered reg-
ularly interspaced short palindromic repeat (CRISPR)-Cas9 genome ed-
iting system. Briefly, a 20-nucleotide (nt) guide sequence adjacent to a
protospacer-adjacent motif (PAM) sequence was selected within the re-
gion of FKS1HS1. This regionwas selected using the online CHOPCHOP
selection tool (24) (https://chopchop.rc.fas.harvard.edu) and is situated
between positions 1892 and 1914 with respect to first ATG codon. The
guide sequence was flanked by pMEL10 sequences (25) to allow homolo-
gous recombination in S. cerevisiae. The guide-pMEL10 sequence was
produced by complementary assembly of primers FKS_crisp_R and
FKS_crisp_F (see Table S2 in the supplemental material). pMEL10 was
prepared by inverse PCRwith primers p426 CRISPR rv and p426 CRISPR
fw (see Table S2 in the supplementalmaterial) followed byDpnI digestion
as described by Mans et al. (25). Three different repair fragments were
produced, with each containing the desired FKS1mutation with overlap-
ping primers for the FKS1 mutations S636Y, S643P, and S643Y. Primer
pairs using left and right primers are indicated in Table S2 in the supple-
mental material and were used for PCR amplification to produce 120-bp
repair fragments. Genome editingwas performed by combining pMEL10,
the guide-pMEL10 fragment, and each of the repair fragments and by
transformation into S. cerevisiae IMX581 (25). Transformation of S.
cerevisiae was performed as described previously (25), and selection was
carried out in YNB agar lacking uracil. Verifications of introduced muta-
tions were performed by PCR amplification with primers FKS1verif left
and FKS1verif right (see Table S2 in the supplementalmaterial) of theHS1
region and by sequence analysis as described above. Derivatives from
IMX581 are described in Table S3 in the supplemental material.
-Glucan measurements. Patient blood samples were drawn, and
sera were stored at80°C and subjected to batch analysis with duplicate
testing by Fungitell on an ELx808IU microplate reader (Associates of
Cape Cod, East Falmouth, MA) per the manufacturer’s package insert.
Samples with -glucan (BG) values above the upper limit of quantifica-
tion (500 pg/ml) were diluted (58 of 921; 6%). The mean BG values of
duplicates were used for data analysis.
Galactomannan assay. The Bio-Rad Platelia Aspergillus antigen (Ag)
assay was used tomeasure galactomannan levels. This immunoenzymatic
sandwich microplate assay enabled the detection of Aspergillus galacto-
mannan antigen in serum and bronchoalveolar lavage fluid samples
through the use of rat EBA-2monoclonal antibodies. Results are reported
in standard international units (provided as index values with limits of
0.25 to 0.5), which refer to the absorbance (optical density) of specimens
determined with a spectrophotometer set at 450 nm.
TDM. Therapeutic drug monitoring (TDM) was performed accord-
ing to published procedures with multiplex ultraperformance liquid
chromatography-tandemmass spectrometry methods that enable simul-
taneous quantification in plasma of azoles and candins (26).
Nucleotide sequence accession numbers. C. lusitaniae sequences
were deposited in GenBank under accession no. JF304613 and JF304615.
Sequences from isolates P1 to P5 were deposited in GenBank under ac-
cession numbers KM383792 to KM383795 and KP100692.
RESULTS
Case report. A 3-year-old female with hematologic and central
nervous system (CNS) relapse of acute myeloid leukemia (AML)
was started on high-dose cytarabine and clofarabine as second-
line induction. She remained profoundly neutropenic over the
following 4 months until her death. Three weeks after induction
chemotherapy, she presented with fever and diarrhea. She had
been on prolonged prophylactic treatment with intravenous (i.v.)
liposomal AMB (3 mg/kg of body weight/day) and broad-spec-
trum antibiotics for over amonth. Clinical and radiological exam-
ination showed severe enterocolitis. As such invasive C. lusitaniae
candidiasis was suspected based on the documentation of C. lus-
itaniae in her stools and a positive mannan assay result (immu-
noenzyme assay, 500 pg/ml) (27, 28). Blood culture results were,
however, negative. Given the lack of validated clinical breakpoint
definitions forC. lusitaniae, we used those available forC. albicans
(29, 30). Given the profile (P1; see Fig. 1 and Table 2 for suscepti-
bility profiles) of the susceptibility of the recovered C. lusitaniae
isolate to echinocandins (CAS, micafungin [MICA], and anidula-
fungin [ANI] MICs, 0.5 g/ml, 0.03 g/ml, and 0.06 g/ml, re-
spectively), to azoles (FLC MIC, 0.25 g/ml) and to AMB (MIC,
0.06 g/ml), she was started on CAS at 100 mg/m2/day, which
resulted in clinical improvement. While she was on CAS for 2
weeks with measured plasma levels of 4.3 mg/liter, she presented
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with C. lusitaniae candidemia (isolate P2; see Fig. 1), which was
resistant to all echinocandins (CAS, MICA, and ANI MICs, 4 g/
ml, 16 g/ml, and 2 g/ml, respectively) and AMB (MIC, 2 g/
ml) but not to azoles (FLC MIC, 0.25 g/ml) or 5-fluorocytosine
(5-FC) (MIC, 0.5 g/ml). At the same time, she presented with
visceral adenovirus disease (subtype 41 F) with high viral loads in
her blood (2 105 copies [cp]/ml) and stool (4 109 cp/ml) (31).
She was therefore started on intravenous cidofovir. No endovas-
cular source was documented, and repeat computed tomography
(CT) showed severe enterocolitis but no hepatosplenic nor pul-
monary lesions. Intravenous FLC (12 mg/kg/day) was added to
CAS, with documented plasma levels of 12.1 mg/liter and 4.4 mg/
liter, respectively (26). While she was on combined therapy for a
week, she presented with a new onset of fever and diarrhea with
simultaneous positive blood cultures forC. lusitaniae (isolate P2).
Combined therapy with CAS was maintained pending synergistic
testing results as we suspected the presence of different strains,
among which some could still have been CAS sensitive. In addi-
tion, we preferred maintaining a fungicidal drug in a profoundly
neutropenic host. Synergistic testing showed no benefit of com-
bined CAS/FLC therapy (data not shown). Therefore, CAS was
stopped after an overall duration of 6 weeks. Her blood culture
results remained persistently positive (P2) for a week despite clin-
ical improvement, adequate drug levels, and no documented en-
dovascular source. All intravenous lines were changed. While be-
ing on combined therapy (CAS/FLC) for 3weeks, followed by FLC
monotherapy for 1 week with adequate drug levels, she presented
with a new onset of fever, a maculopapular rash, profuse diarrhea,
and candidemia. Surprisingly, her new C. lusitaniae isolate (P3;
see Fig. 1) was susceptible to echinocandins (CAS and MICA
MICs, 0.5 g/ml and 0.03 g/ml, respectively) and AMB (MIC,
0.25g/ml) but resistant to azoles (FLCMIC, 32g/ml) and 5-FC
(MIC, 64 g/ml). CAS (100 mg/m2/day) was added again to FLC
to avoid the emergence of C. lusitaniae strains exhibiting either
echinocandin resistance or azole resistance. While being on com-
bined therapy for 3 weeks (CAS plasma level, 2.5 mg/liter; FLC
plasma level, 9.3 mg/liter), she presented with a new onset of can-
didemia, with a C. lusitaniae isolate (P4; see Fig. 1) resistant to
echinocandins (CAS, MICA, and ANI MICs, 8 g/ml, 16 g/ml,
and 4 g/ml, respectively), FLC (MIC, 8 g/ml), and 5-FC (MIC,
32 g/ml) but susceptible to AMB (MIC, 0.06 g/ml). CAS was
therefore replaced by AMB (5 mg/kg/day). FLC was replaced by
voriconazole (VORI) (9 mg/kg twice a day [b.i.d.]; plasma level,
1.5 mg/liter), as probable invasive pulmonary aspergillosis (32)
was suspected based on new pulmonary infiltrates on a repeat CT
and a positive blood galactomannan assay result (enzyme-linked
immunoassay [EIA], 6.54 pg/ml) (32). Although AMB mono-
therapy would have covered both fungal infections, combined
therapy was preferred because of the severity of both infections.
Further disease evolution was marked by persistent fever and di-
arrhea associated with persistent adenovirus viremia (106 cp/ml).
A week later, she underwent allogeneic hematopoietic stem cell
transplantation (HSCT) after receiving conditioning chemother-
apy with busulfan, anti-thymocyte globulins (ATG), and fludara-
bine. While she was on AMB and VORI at subtherapeutic (0.7
mg/liter) levels for almost 2 weeks, her blood cultures were again
found to be positive for C. lusitaniae. At that point, she was con-
tinued on the same antifungal regimen. An isolate (P5) with a
susceptibility profile similar to that of P2 (CAS, AMB, and FLC
MICs, 8, 2.0, and 0.125g/ml, respectively) was recovered during
this period. All her lines were changed, an endovascular source
was ruled out, and a repeat CT scan still evidenced severe entero-
colitis. The further evolution of her disease state was marked with
progressive fulminant hepatitis, renal dysfunction, and death,
mainly attributed to drug toxicities and disseminated adenoviral
infection. The latter was corroborated by persistently high-level
viremia (5 108 cp/ml) despite her having received 11 doses of
intravenous cidofovir (5 mg/kg) but no administration of adeno-
FIG 1 Summary of the susceptibility profiles of C. lusitaniae isolates. MIC values were obtained with the EUCAST method as described in Materials and
Methods. Dates of isolate collection are given at the top of the figure as follows: 9.06, 9 June 2013; 1-8-15.07, 1, 8, and 15 July 2013; 1.08, 1 August 2013; 20.08,
20 August 2013; 20.09, 20 September 2013. Resistance and susceptibility are highlighted by red and yellow sectors, respectively. Details of the types of treatments
and their durations and therapeutic drug monitoring (TDM) are given at the bottom of the figure. BC, blood culture; NA, not available.
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virus-specific cytotoxic T lymphocytes. Invasive candidiasis and
pulmonary aspergillosis probably also contributed to her death.
Autopsy was refused by the family.
Molecular analysis of C. lusitaniae strains. The RFLP and
RAPDprofiles of recovered isolates P1 to P5were identical (Fig. 2;
see also Fig. S1 in the supplementalmaterial) and thus suggest that
the strains originated from the same parent.Molecular analyses of
candin resistance revealed two novel FKS1mutations in resistant
isolates (S638Y in P2 and S631Y in P4). These mutations corre-
spond to positions S638 and S645 in FKS1 ofC. albicans; the latter
position is known to be involved inCAS resistance (S645F, -P, and
-Y) (Fig. 3) (8, 33). Interestingly, the last recovered isolate, P5,
with a drug susceptibility profile similar to that of P2, exhibited
the FKS1 S638P substitution (corresponding to S645P in C. albi-
cans), which was different from that exhibited by P2 (S638Y).
Thus, P2 and P5 are of distinct genotypes. No mutations were
observed in HS2 of FKS1 (data not shown). As summarized in
Table 1, CAS resistance was associated with cross-resistance to
other candins (MICA MICs, 8 to 16 g/ml; ANI MICs, 2 to 4
g/ml) and, surprisingly, with resistance to AMB (MIC, 2g/ml)
in P2.
Since mutation S631Y in C. lusitaniae and the equivalent mu-
tation, Ser638, in C. albicans have not yet been reported to be
involved in candin resistance, we performed site-directed mu-
tagenesis analysis in FKS1 from S. cerevisiae at the equivalent po-
sition (Ser636) to produce a S636Y variant. FKS1 variants at po-
sition Ser643 (S643Y and S643P), which is equivalent to position
Ser638 in C. lusitaniae, were also produced as comparisons. A
recent genome editing system (CRISPR-Cas) was used for this
purpose (25) and thus introduced the desired mutations at the S.
cerevisiae genomic FKS1 locus. The resulting isolates exhibited
resistance to all three candins compared to the wild type (Table 2).
The FKS1 S636Y mutation showed CAS, MICA, and ANI MICs
that had increased by 32-, 32-, and 16-fold, respectively, compared
FIG 2 RFLP and RAPD analysis of C. lusitaniae isolates P1 to P5. RFLP anal-
ysis was carried out with EcoRI andMspI. RFLP profiles are shown in Fig. S1 in
the supplemental material. RAPD analysis was performed as described in Ma-
terials and Methods. Identical patterns of ethidium bromide-stained profiles
suggest a high-level relationship between the strains. Lambda phage DNAs
digested by HindIII were loaded as standard sizes. A separate C. lusitaniae
isolate (Sanglard laboratory collection) was used as a control for RAPD anal-
ysis.
FIG 3 Alignments of FKS1HS1 regions fromCandida spp. TheC. lusitaniae andC. albicans SC5314 data were alignedwith chromatograms of FKS1HS1 regions
from C. lusitaniae isolates P1 to P5 as indicated. Sequences from isolates P1 to P5 were deposited in GenBank.
Asner et al.
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to the wild type (Table 2). The mutations S643Y and S643P in-
creased candin MICs from 32- to 256-fold compared to the wild
type (Table 2); thus, the data suggest that they have a greater im-
pact on candin resistance than S636Y. In any case, position Ser636
(Ser631 in C. lusitaniae) can be added as another novel site rele-
vant for candin resistance.
Azole resistance in C. albicans is mediated by several mecha-
nisms, among which transport-related mechanisms involving ei-
ther major facilitator superfamily (MFS) genes or ATP-binding
cassette (ABC) transporter genes are themost frequently reported
(34). Few studies have explored azole resistance and the involve-
ment of major drug transporters. Among these, a recent report by
Reboutier et al. (23) suggested upregulation of MFS7 in docu-
mented FLC-resistant isolates. As illustrated in Fig. 4, we corrob-
orated the overexpression of MFS7 in FLC-resistant C. lusitaniae
isolates P3 and P4 (50- and 32-fold compared to P1, respectively).
No expression variations in azole resistance genes belonging to the
ABC transporter family or to ERG11 (target of azoles) were iden-
tified among our C. lusitaniae isolates (Fig. 4). Interestingly, FLC
resistance in P3 and P4 correlated with an elevated VORI MIC
(0.25 g/ml, compared with 0.008 g/ml for P1, P2, and P5) but
also with resistance to 5-FC (MIC, 32 g/ml).
In contrast to our findings, other studies reported 5-FC/azole
cross-resistance correlating with mutations of FCY1 and FCY2
genes encoding cytosine deaminase andpurine-cytosine permease
involved in 5-FC transport andmetabolism (35). Thesemutations
were documented following simultaneous use of 5-FC and azoles
in susceptibility assays, thus suggesting a different mechanism for
5-FC-azole cross-resistance. Indeed, no mutations in 5-FC resis-
tance genes (FCY1 and FCY2) were detected in the P3 and P4
isolates (data not shown). Analysis of FUR1, encoding uracil
phosphoribosyl transferase, was not conducted as isolates P1 to P5
were not resistant to 5-fluorouracil, which is commonly reported
among FUR1-deficient isolates (data not shown) (36).
DISCUSSION
This clinical report describes acquired resistance ofC. lusitaniae to
all common antifungals in a profoundly neutropenic host with
severe enterocolitis. When simultaneous combinations of resis-
tance to 2 ormore different drug classes occur, which was the case
in the present study, the phenotype is referred to as multidrug
resistance (MDR). While MDR is not a common phenotype
among fungal pathogens, it was reported earlier in C. glabrata,
with simultaneous acquisition of resistance to echinocandins and
to azoles and separate acquisition of resistance to 5-FC (37). In the
United States, a significant proportion (30% to 40%) of echino-
candin-resistant isolates are also resistant to azoles (38, 39).While
a recent study (40) suggested an association betweenMDRand the
use of echinocandins and azoles, another investigation (41) de-
scribed MDR to echinocandins, azoles, and amphotericin B in C.
glabrata isolates recovered from a neutropenic patient with pro-
longed fever.
Antifungal resistance is a growing concern worldwide (42–44);
however, less is known about themechanism of resistance to echi-
nocandins inC. lusitaniae. In the present paper, resistance to CAS
was correlated to the identification of 3 novel FKS1 mutations
(S638Y, S638P, and S631Y). Among these, FKS1mutations S638Y
and -P corresponded to C. albicans and S. cerevisiae positions
Ser645 and Ser643, respectively, which are commonly attributed
to echinocandin resistance (45), whereas the remaining FKS1
S631Y mutation corresponded to position Ser638 in C. albicans
TABLE 1 Antifungal susceptibility profiles of C. lusitaniae isolatesa
Date of isolation
Sample
origin Profile
MIC (g/ml)b
FKS1
mutation
MFS7
expression AFFLC CAS MICA ANI AMB 5-FC
9 June 2013 Stool 1 0.25 0.5 0.03 0.06 0.06 0.5 WT No AMB
1 July 2013 Blood 2 0.25 4 (8) 16 (512) 2 (32) 2 0.5 S638Y No CAS
1 August 2013 Blood 3 32 0.5 (1) 0.03 (1) 0.06 (1) 0.25 64 WT Yes FLC
23 August 2013 Blood 4 8 8 (16) 16 (512) 4 (64) 0.06 32 S631Y Yes VORI/CAS
2 September 2013 Stool 4 32 4 (8) 8 (256) 4 (64) 0.125 32 S631Y Yes VORI/AMB
20 September 2013 NA 5 0.125 8 (16) 16 (512) 4 (64) 2 2 S638P No VORI/AMB
a AF, antifungal treatment; NA, not available; WT, wild-type HS1 FKS1 sequence.
b Numbers in parentheses represent relative fold increases in MICs compared to the MIC value of the isolate with profile 1.
TABLE 2 Candin MICs of S. cerevisiae FKS1 mutants
Isolate
MIC (g/ml)a
CAS MICA ANI
S. cerevisiae wild-type IMX581 0.03 0.015 0.03
DSY4762 (FKS1S636Y) 1 (32) 0.5 (32) 0.5 (16)
DSY4763 (FKS1S643Y) 2 (64) 4 (256) 1 (32)
DSY4764 (FKS1S643P) 8 (256) 4 (256) 1 (32)
a MIC assays were performed according to the EUCAST protocol but at 30°C and with
YEPD medium. Numbers in parentheses represent relative fold increases in MICs
compared to the MIC value of the wild type.
FIG 4 qRT-PCR ofC. lusitaniae genes potentially involved in azole resistance.
Results are expressed as means of the results from triplicate biological experi-
ments relative to isolate P1 data.
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and position Ser636 in S. cerevisiae. Here we confirmed that a
mutation at this position can alter candin susceptibility in S.
cerevisiae. The FKS1 S636Y mutation yields lower candin MICs
than S643Y and S643P; thus, one may conclude that Ser636 is less
effective for candin resistance development. In evaluating the rel-
ative increases of candin MICs in C. lusitaniae and S. cerevisiae
compared to their respective wild types (Table 1 and 2), the trends
seenwith the two yeast species are globally similar, with the excep-
tion of the relative MICA MIC increases (32-fold versus 256-fold
and 256-fold for C. lusitaniae and S. cerevisiae, respectively). Such
differencesmight be due to differences in the intrinsic FKS1 struc-
tures of the two species. Similarly to our case report, a recent study
(19) documented isolates ofC. lusitaniae exhibitingmissensemu-
tation S645F in FKS1, which resulted in increasedMICs of several
echinocandins (CAS, MICA, and ANI) following CAS exposure.
In contrast to our report, those isolates were not cross-resistant to
other classes of antifungal drugs (5-FC, FLC, and AMB).
Overexpression of a major facilitator gene (MFS7) was docu-
mented among our FLC-resistant isolates. MFS transporter up-
regulation in Candida spp. is associated with mutations in the
MRR1 transcriptional activator in C. albicans (46). Similar muta-
tions could be suspected in C. lusitaniae strains. In the present
report, FLC resistance was coupled to 5-FC resistance, despite the
lack of 5-FC exposure, thus suggesting that the 5-FC resistance
resulted from FLC resistance. Given that MFS7 upregulation re-
sults in FLC efflux in FLC-resistant strains, a similar mechanism
might be involved in 5-FC-resistant strains. While this hypothesis
remains speculative, mutations responsible for FLC/5-FC cross-
resistance differ from the usual nonsense andmissense mutations
in FCY2 and FCY1 reported in C. lusitaniae strains and should
thus be further explored (35).
Cross-resistance to AMB resistance and candins occurred
without ongoing exposure to AMB (see Fig. 1). The molecular
basis of AMB resistance in C. lusitaniae has not yet been well
documented. While some studies attributed AMB resistance to a
rapidly switching phenotype occurring at a frequency of 102 to
104 (47), other studies attributed it to cell wall reorganization
(48). FKS mutations documented in C. lusitaniae P2 could have
induced cell wall stress, which then could result in AMB resis-
tance. Even if CAS resistance was not associated with AMB resis-
tance in P4 (FKS1 mutation S631Y), this hypothesis should be
further investigated. Such issues could now be addressed using the
genetic tools that have become accessible for use in C. lusitaniae
studies.
The present report illustrates rapid selection of resistant mu-
tants under conditions of drug pressure. The sequential adminis-
tration of specific agents resulted in the emergence of isolates re-
sistant to a specific molecule as illustrated in Fig. 1. Treatments
using CAS and azole and their combination were followed within
days by the selection of CAS- and/or azole-resistant isolates. This
rapid emergence can be facilitated by the haploid nature of C.
lusitaniae. It is also possible that several resistant populations with
P1 to P5 profiles may have coexisted in the patient and that dom-
inant resistance profiles were selected and emerged under condi-
tions of exposure to a specific antifungal agent. As such, the colon
may have been a colonizing reservoir which then seeded infection
and different resistance phenotypes. Long-lasting neutropenia
and enterocolitis certainly also contributed to this mechanism.
Rapid emergence of multidrug-resistant mutants under condi-
tions of combined therapy reinforces the idea of a need for limit-
ing dual therapy to exceptional situations.
ACKNOWLEDGMENTS
We are thankful for technical assistance from F. Ischer and for isolate
collection and maintenance by C. Durussel. We are indebted to R. Zbin-
den of the University of Zurich, Institut für Medizinische Mikrobiologie,
for helping in isolate collection.
This study was partially financed by a Swiss Research National Foun-
dation grant (31003A_146936/1) to D.S. We thank Astellas, Pfizer, and
Merck for providing pure antifungal substances.
REFERENCES
1. Favel A, Michel-Nguyen A, Peyron F, Martin C, Thomachot L, Datry A,
Bouchara JP, Challier S, Noel T, Chastin C, Regli P. 2003. Colony
morphology switching of Candida lusitaniae and acquisition ofmultidrug
resistance during treatment of a renal infection in a newborn: case report
and review of the literature. DiagnMicrobiol Infect Dis 47:331–339. http:
//dx.doi.org/10.1016/S0732-8893(03)00094-4.
2. Atkinson BJ, Lewis RE, Kontoyiannis DP. 2008. Candida lusitaniae
fungemia in cancer patients: risk factors for amphotericin B failure and
outcome. MedMycol 46:541–546. http://dx.doi.org/10.1080/1369378080
1968571.
3. Lockhart SR, Iqbal N, Cleveland AA, Farley MM, Harrison LH, Bolden
CB, Baughman W, Stein B, Hollick R, Park BJ, Chiller T. 2012. Species
identification and antifungal susceptibility testing of Candida blood-
stream isolates from population-based surveillance studies in two U.S.
cities from 2008 to 2011. J ClinMicrobiol 50:3435–3442. http://dx.doi.org
/10.1128/JCM.01283-12.
4. Abruzzo GK, Flattery AM, Gill CJ, Kong L, Smith JG, Pikounis VB,
Balkovec JM, Bouffard AF, Dropinski JF, Rosen H, Kropp H, Bartizal
K. 1997. Evaluation of the echinocandin antifungal MK-0991 (L-
743,872): efficacies in mouse models of disseminated aspergillosis, candi-
diasis, and cryptococcosis. Antimicrob Agents Chemother 41:2333–2338.
5. Perlin DS. 2011. Echinocandin-resistant Candida: molecular methods
and phenotypes. Curr Fungal Infect Rep 5:113–119. http://dx.doi.org/10
.1007/s12281-011-0054-x.
6. Baixench MT, Aoun N, Desnos-Ollivier M, Garcia-Hermoso D,
Bretagne S, Ramires S, Piketty C, Dannaoui E. 2007. Acquired resistance
to echinocandins in Candida albicans: case report and review. J Antimi-
crob Chemother 59:1076–1083. http://dx.doi.org/10.1093/jac/dkm095.
7. Balashov SV, Park S, Perlin DS. 2006. Assessing resistance to the echi-
nocandin antifungal drug caspofungin in Candida albicans by profiling
mutations in FKS1. Antimicrob Agents Chemother 50:2058–2063. http:
//dx.doi.org/10.1128/AAC.01653-05.
8. Desnos-Ollivier M, Bretagne S, Raoux D, Hoinard D, Dromer F,
Dannaoui E; European Committee on Antibiotic Susceptibility Testing.
2008. Mutations in the fks1 gene in Candida albicans, C. tropicalis, and C.
krusei correlate with elevated caspofungin MICs uncovered in AM3 me-
dium using the method of the European Committee on Antibiotic Sus-
ceptibility Testing. Antimicrob Agents Chemother 52:3092–3098. http:
//dx.doi.org/10.1128/AAC.00088-08.
9. Garcia-Effron G, Chua DJ, Tomada JR, DiPersio J, Perlin DS, Ghan-
noum M, Bonilla H. 2010. Novel FKS mutations associated with echino-
candin resistance in Candida species. Antimicrob Agents Chemother 54:
2225–2227. http://dx.doi.org/10.1128/AAC.00998-09.
10. Kahn JN, Garcia-Effron G, Hsu MJ, Park S, Marr KA, Perlin DS. 2007.
Acquired echinocandin resistance in a Candida krusei isolate due tomod-
ification of glucan synthase. Antimicrob Agents Chemother 51:1876–
1878. http://dx.doi.org/10.1128/AAC.00067-07.
11. Park S, Kelly R, Kahn JN, Robles J, Hsu MJ, Register E, Li W, Vyas V,
Fan H, Abruzzo G, Flattery A, Gill C, Chrebet G, Parent SA, Kurtz M,
Teppler H, Douglas CM, Perlin DS. 2005. Specific substitutions in the
echinocandin target Fks1p account for reduced susceptibility of rare lab-
oratory and clinical Candida sp. isolates. Antimicrob Agents Chemother
49:3264–3273. http://dx.doi.org/10.1128/AAC.49.8.3264-3273.2005.
12. Arendrup MC, Garcia-Effron G, Lass-Florl C, Lopez AG, Rodriguez-
Tudela JL, Cuenca-Estrella M, Perlin DS. 2010. Echinocandin suscepti-
bility testing of Candida species: comparison of EUCAST EDef 7.1, CLSI
M27-A3, Etest, disk diffusion, and agar dilution methods with RPMI and
Asner et al.
7720 aac.asm.org December 2015 Volume 59 Number 12Antimicrobial Agents and Chemotherapy
 o
n
 January 6, 2019 by guest
http://aac.asm
.org/
D
ow
nloaded from
 
isosensitest media. Antimicrob Agents Chemother 54:426–439. http://dx
.doi.org/10.1128/AAC.01256-09.
13. Arendrup MC, Perlin DS. 2014. Echinocandin resistance: an emerging
clinical problem? Curr Opin Infect Dis 27:484–492. http://dx.doi.org/10
.1097/QCO.0000000000000111.
14. Pfaller MA, Moet GJ, Messer SA, Jones RN, Castanheira M. 2011.
Candida bloodstream infections: comparison of species distributions and
antifungal resistance patterns in community-onset and nosocomial iso-
lates in the SENTRY Antimicrobial Surveillance Program, 2008–2009.
Antimicrob Agents Chemother 55:561–566. http://dx.doi.org/10.1128
/AAC.01079-10.
15. Eddouzi J, Hofstetter V, Groenewald M, Manai M, Sanglard D. 2013.
Characterization of a new clinical yeast species, Candida tunisiensis sp.
nov., isolated from a strain collection from Tunisian hospitals. J Clin Mi-
crobiol 51:31–39. http://dx.doi.org/10.1128/JCM.01627-12.
16. Sanchez V, Vazquez JA, Barth-Jones D, Dembry L, Sobel JD, Zervos
MJ. 1992. Epidemiology of nosocomial acquisition of Candida lusitaniae.
J Clin Microbiol 30:3005–3008.
17. Sanglard D, Ischer F, MonodM, Bille J. 1996. Susceptibilities of Candida
albicans multidrug transporter mutants to various antifungal agents and
other metabolic inhibitors. Antimicrob Agents Chemother 40:2300–
2305.
18. Schneider CA, RasbandWS, Eliceiri KW. 2012. NIH Image to ImageJ: 25
years of image analysis. Nat Methods 9:671–675. http://dx.doi.org/10
.1038/nmeth.2089.
19. Desnos-Ollivier M, Moquet O, Chouaki T, Guerin AM, Dromer F.
2011. Development of echinocandin resistance in Clavispora lusitaniae
during caspofungin treatment. J Clin Microbiol 49:2304–2306. http://dx
.doi.org/10.1128/JCM.00325-11.
20. Eddouzi J, Parker JE, Vale-Silva LA, Coste A, Ischer F, Kelly S, Manai
M, Sanglard D. 2013. Molecular mechanisms of drug resistance in clinical
Candida species isolated from Tunisian hospitals. Antimicrob Agents
Chemother 57:3182–3193. http://dx.doi.org/10.1128/AAC.00555-13.
21. Ferrari S, Sanguinetti M, Torelli R, Posteraro B, Sanglard D. 2011.
Contribution of CgPDR1-regulated genes in enhanced virulence of azole-
resistant Candida glabrata. PLoS One 6:e17589. http://dx.doi.org/10.1371
/journal.pone.0017589.
22. Sanguinetti M, Posteraro B, Fiori B, Ranno S, Torelli R, Fadda G. 2005.
Mechanisms of azole resistance in clinical isolates of Candida glabrata
collected during a hospital survey of antifungal resistance. Antimicrob
Agents Chemother 49:668–679. http://dx.doi.org/10.1128/AAC.49.2.668
-679.2005.
23. Reboutier D, Piednoel M, Boisnard S, Conti A, Chevalier V, Florent M,
Gibot-Leclerc S, Da Silva B, Chastin C, Fallague K, Favel A, Noel T,
Ruprich-Robert G, Chapeland-Leclerc F, Papon N. 2009. Combination
of different molecular mechanisms leading to fluconazole resistance in a
Candida lusitaniae clinical isolate. Diagn Microbiol Infect Dis 63:188–
193. http://dx.doi.org/10.1016/j.diagmicrobio.2008.10.019.
24. Montague TG, Cruz JM, Gagnon JA, Church GM, Valen E. 2014.
CHOPCHOP: a CRISPR/Cas9 and TALEN web tool for genome edit-
ing. Nucleic Acids Res 42:W401–W407. http://dx.doi.org/10.1093/nar
/gku410.
25. Mans R, van Rossum HM, Wijsman M, Backx A, Kuijpers NG, van den
Broek M, Daran-Lapujade P, Pronk JT, van Maris AJ, Daran JM. 2015.
CRISPR/Cas9: a molecular Swiss army knife for simultaneous introduc-
tion of multiple genetic modifications in Saccharomyces cerevisiae. FEMS
Yeast Res 15:fov004. http://dx.doi.org/10.1093/femsyr/fov004.
26. Decosterd LA, Rochat B, Pesse B, Mercier T, Tissot F, Widmer N, Bille
J, Calandra T, Zanolari B, Marchetti O. 2010. Multiplex ultra-
performance liquid chromatography-tandemmass spectrometry method
for simultaneous quantification in human plasma of fluconazole, itra-
conazole, hydroxyitraconazole, posaconazole, voriconazole, voricona-
zole-N-oxide, anidulafungin, and caspofungin. Antimicrob Agents Che-
mother 54:5303–5315. http://dx.doi.org/10.1128/AAC.00404-10.
27. Marchetti O, Lamoth F, Mikulska M, Viscoli C, Verweij P, Bretagne S;
European Conference on Infections in Leukemia (ECIL) Laboratory
Working Groups. 2012. ECIL recommendations for the use of biological
markers for the diagnosis of invasive fungal diseases in leukemic patients
and hematopoietic SCT recipients. BoneMarrowTransplant 47:846–854.
http://dx.doi.org/10.1038/bmt.2011.178.
28. Mikulska M, Calandra T, Sanguinetti M, Poulain D, Viscoli C; Third
European Conference on Infections in Leukemia Group. 2010. The use
of mannan antigen and anti-mannan antibodies in the diagnosis of inva-
sive candidiasis: recommendations from the Third European Conference
on Infections in Leukemia. Crit Care 14:R222. http://dx.doi.org/10.1186
/cc9365.
29. Pfaller MA, Andes D, Diekema DJ, Espinel-Ingroff A, Sheehan D; CLSI
Subcommittee for Antifungal Susceptibility Testing. 2010. Wild-type
MICdistributions, epidemiological cutoff values and species-specific clin-
ical breakpoints for fluconazole and Candida: time for harmonization of
CLSI and EUCAST broth microdilution methods. Drug Resist Updat 13:
180–195. http://dx.doi.org/10.1016/j.drup.2010.09.002.
30. Fothergill AW, Sutton DA, McCarthy DI, Wiederhold NP. 2014. Impact
of new antifungal breakpoints on antifungal resistance in Candida species.
J Clin Microbiol 52:994–997. http://dx.doi.org/10.1128/JCM.03044-13.
31. Lion T. 2014. Adenovirus infections in immunocompetent and immuno-
compromised patients. Clin Microbiol Rev 27:441–462. http://dx.doi.org
/10.1128/CMR.00116-13.
32. De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra
T, Pappas PG, Maertens J, Lortholary O, Kauffman CA, Denning DW,
Patterson TF, Maschmeyer G, Bille J, Dismukes WE, Herbrecht R,
Hope WW, Kibbler CC, Kullberg BJ, Marr KA, Muñoz P, Odds FC,
Perfect JR, Restrepo A, Ruhnke M, Segal BH, Sobel JD, Sorrell TC,
Viscoli C, Wingard JR, Zaoutis T, Bennett JE; European Organization
for Research and Treatment of Cancer/Invasive Fungal Infections Co-
operative Group; National Institute of Allergy and Infectious Diseases
Mycoses Study Group (EORTC/MSG) Consensus Group. 2008. Revised
definitions of invasive fungal disease from the European Organization for
Research and Treatment of Cancer/Invasive Fungal Infections Coopera-
tive Group and the National Institute of Allergy and Infectious Diseases
Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis
46:1813–1821. http://dx.doi.org/10.1086/588660.
33. Desnos-Ollivier M, Dromer F, Dannaoui E. 2008. Detection of caspo-
fungin resistance inCandida spp. by Etest. J ClinMicrobiol 46:2389–2392.
http://dx.doi.org/10.1128/JCM.00053-08.
34. Sanglard D, Odds FC. 2002. Resistance of Candida species to antifungal
agents: molecular mechanisms and clinical consequences. Lancet Infect
Dis 2:73–85. http://dx.doi.org/10.1016/S1473-3099(02)00181-0.
35. Florent M, Noel T, Ruprich-Robert G, Da Silva B, Fitton-Ouhabi V,
Chastin C, Papon N, Chapeland-Leclerc F. 2009. Nonsense and missense
mutations in FCY2 and FCY1 genes are responsible for flucytosine resis-
tance and flucytosine-fluconazole cross-resistance in clinical isolates of
Candida lusitaniae. Antimicrob Agents Chemother 53:2982–2990. http:
//dx.doi.org/10.1128/AAC.00880-08.
36. Papon N, Noel T, Florent M, Gibot-Leclerc S, Jean D, Chastin C,
Villard J, Chapeland-Leclerc F. 2007. Molecular mechanism of flucyto-
sine resistance inCandida lusitaniae: contribution of the FCY2, FCY1, and
FUR1 genes to 5-fluorouracil and fluconazole cross-resistance. Antimi-
crob Agents Chemother 51:369–371. http://dx.doi.org/10.1128/AAC
.00824-06.
37. Chapeland-Leclerc F, Hennequin C, Papon N, Noel T, Girard A,
Socie G, Ribaud P, Lacroix C. 2010. Acquisition of flucytosine, azole,
and caspofungin resistance in Candida glabrata bloodstream isolates
serially obtained from a hematopoietic stem cell transplant recipient.
Antimicrob Agents Chemother 54:1360–1362. http://dx.doi.org/10
.1128/AAC.01138-09.
38. Grossman NT, Chiller TM, Lockhart SR. 2014. Epidemiology of echi-
nocandin resistance in Candida. Curr Fungal Infect Rep 8:243–248. http:
//dx.doi.org/10.1007/s12281-014-0209-7.
39. Pham CD, Iqbal N, Bolden CB, Kuykendall RJ, Harrison LH, Farley
MM, Schaffner W, Beldavs ZG, Chiller TM, Park BJ, Cleveland AA,
Lockhart SR. 2014. Role of FKS mutations in Candida glabrata: MIC
values, echinocandin resistance, and multidrug resistance. Antimicrob
Agents Chemother 58:4690 – 4696. http://dx.doi.org/10.1128/AAC
.03255-14.
40. Farmakiotis D, Tarrand JJ, Kontoyiannis DP. 2014. Drug-resistant Can-
dida glabrata infection in cancer patients. Emerg Infect Dis 20:1833–1840.
41. Cho EJ, Shin JH, Kim SH, Kim HK, Park JS, Sung H, Kim MN, Im HJ.
2015. Emergence of multiple resistance profiles involving azoles, echino-
candins and amphotericin B in Candida glabrata isolates from a neutro-
penia patient with prolonged fungaemia. J Antimicrob Chemother 70:
1268–1270. http://dx.doi.org/10.1093/jac/dku518.
42. Laverdière M, Lalonde RG, Baril JG, Sheppard DC, Park S, Perlin DS.
2006. Progressive loss of echinocandin activity following prolonged use
for treatment of Candida albicans oesophagitis. J Antimicrob Chemother
57:705–708. http://dx.doi.org/10.1093/jac/dkl022.
Candida lusitaniae and Multidrug Antifungal Resistance
December 2015 Volume 59 Number 12 aac.asm.org 7721Antimicrobial Agents and Chemotherapy
 o
n
 January 6, 2019 by guest
http://aac.asm
.org/
D
ow
nloaded from
 
43. Perlin DS. 2007. Resistance to echinocandin-class antifungal drugs. Drug
Resist Updat 10:121–130. http://dx.doi.org/10.1016/j.drup.2007.04.002.
44. Snelders E, van der Lee HA, Kuijpers J, Rijs AJ, Varga J, Samson RA,
Mellado E, Donders AR, Melchers WJ, Verweij PE. 2008. Emergence of
azole resistance inAspergillus fumigatus and spreadof a single resistancemecha-
nism. PLoSMed 5:e219. http://dx.doi.org/10.1371/journal.pmed.0050219.
45. Pfaller MA, Diekema DJ, Andes D, Arendrup MC, Brown SD, Lockhart
SR, Motyl M, Perlin DS, CLSI Subcommittee for Antifungal Testing.
2011. Clinical breakpoints for the echinocandins and Candida revisited:
integration of molecular, clinical, and microbiological data to arrive at
species-specific interpretive criteria. Drug Resist Updat 14:164–176. http:
//dx.doi.org/10.1016/j.drup.2011.01.004.
46. Dunkel N, Blass J, Rogers PD, Morschhauser J. 2008. Mutations in the
multi-drug resistance regulatorMRR1, followed by loss of heterozygosity,
are themain cause ofMDR1 overexpression in fluconazole-resistant Can-
dida albicans strains. Mol Microbiol 69:827–840. http://dx.doi.org/10
.1111/j.1365-2958.2008.06309.x.
47. Miller NS, Dick JD, Merz WG. 2006. Phenotypic switching in Candida
lusitaniae on copper sulfate indicator agar: association with amphotericin
B resistance and filamentation. J Clin Microbiol 44:1536–1539. http://dx
.doi.org/10.1128/JCM.44.4.1536-1539.2006.
48. GhannoumMA, Rice LB. 1999. Antifungal agents: mode of action, mech-
anisms of resistance, and correlation of these mechanisms with bacterial
resistance. Clin Microbiol Rev 12:501–517.
Asner et al.
7722 aac.asm.org December 2015 Volume 59 Number 12Antimicrobial Agents and Chemotherapy
 o
n
 January 6, 2019 by guest
http://aac.asm
.org/
D
ow
nloaded from
 
